2025-10549Proposed RuleWallet

FDA Considers Easier Path for Certain Cancer-Linked Tests

Published Date: 6/11/2025

Proposed Rule

Summary

The FDA wants to change the rules for certain cancer test systems called in situ hybridization (ISH) tests. These tests will move from a strict approval process to a simpler one with special safety rules, making it easier and faster for companies to get them to doctors and patients. Labs and companies using or making these tests should get ready to comment by August 11, 2025, and expect new rules soon that could save time and money.

Analyzed Economic Effects

5 provisions identified: 4 benefits, 0 costs, 1 mixed.

Manufacturers: Shift from PMA to 510(k)

The FDA proposes to reclassify certain in situ hybridization (ISH) oncology test systems from class III (requiring a premarket approval (PMA)) into class II, so manufacturers would submit a premarket notification (510(k)) instead of a PMA. The rule says the 510(k) pathway is generally less burdensome and more cost-effective and typically results in a shorter review timeline compared to a PMA.

Patients: Potentially faster, wider access to ISH tests

FDA states the reclassification may provide more timely access to these ISH oncology tests and could enable more manufacturers to develop them so patients benefit from increased access to appropriately safe and effective tests. The proposal says this change could result in shorter premarket review timelines and increased availability of these tests.

Special controls to reduce false test risks

FDA proposes specific 'special controls' for these ISH oncology test systems to address risks the Agency identified—such as false positive or false negative results, failures to perform as intended, and incorrect interpretation of results—so that these devices, with special controls plus general controls, provide reasonable assurance of safety and effectiveness.

Manufacturers: Use of Predetermined Change Control Plans

FDA notes manufacturers may use Predetermined Change Control Plans (PCCPs) to implement certain future device modifications without submitting a new 510(k) for each significant change, if the PCCP is reviewed and authorized by FDA under section 515C of the FD&C Act.

510(k) submissions will still be required

FDA explicitly states it does not intend to exempt these proposed class II ISH devices from premarket notification; if the order is finalized, persons intending to market these devices must submit a 510(k) and receive clearance before marketing.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
6/11/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register